Angelini Pharma: new data on cenobamate demonstrate prolonged benefits in epilepsy treatment

Introduction to the new clinical data

Angelini Pharma recently presented the results of long-term clinical studies on cenobamate, a drug approved for the treatment of focal epilepsy in adults. These findings, shared at the 15th European Epilepsy Congress (EEC) in Rome, highlight a sustained reduction in seizures and an improved tolerability profile over the long term.

Study C017 extension: five years of efficacy

One of the key studies presented, the post-hoc analysis of the open-label extension study C017, showed that cenobamate offers long-lasting benefits over a five-year period. These results were observed in patients with uncontrolled focal epilepsy, covering various etiologies, including the difficult-to-treat Mesial Temporal Sclerosis (MTS).

These findings confirm cenobamate’s importance as a long-term therapy for a wide range of epilepsy patients, offering better seizure control.

Retention rates: success after three years of treatment

Another significant result comes from the post-hoc analysis of the C021 study, which demonstrated high retention rates for cenobamate treatment after three years. These rates ranged from 60.3% to 77.9%, regardless of etiology, underscoring the safety and tolerability of the drug in the long term.

Retention rates are a key indicator of the effectiveness of an anti-seizure medication, and these results suggest that cenobamate could be a valid option for patients with drug-resistant epilepsy.

Tolerability profile: fewer adverse events with one drug

A third analysis highlighted that adding cenobamate to only one other anti-seizure medication (ASM) improved its tolerability profile compared to its use with two or more ASMs. Patients treated with cenobamate and a single ASM experienced fewer adverse events and quicker resolution of these events, showing potential benefits when used earlier in therapy.

Future perspectives

These new data reinforce cenobamate’s role as an effective and well-tolerated treatment for drug-resistant focal epilepsy. Angelini Pharma remains committed to researching innovative solutions to improve the lives of people with epilepsy, aiming to reduce seizures and enhance patients’ quality of life.